NCT07441460 2026-03-02
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
Clinical Trials
8 trialsNCT07300475 2026-02-13
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07370506 2026-01-29
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
Phase 1/2 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06404463 2024-05-08
QUEEN-Neo
Fudan University
Phase 2 Not yet recruiting
NCT06371807 2024-04-17
KEYPARTNER
Fundacao Champalimaud
Phase 2 Not yet recruiting
NCT05287308 2022-03-31
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
ChineseAMS
Phase NA Not yet recruiting
NCT04301739 2020-03-12
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Shanghai Henlius Biotech
Phase 3 Not yet recruiting